Signal Genetics, a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced New York State Department of Health approval of its MyPRS (Myeloma Prognostic Risk Signature) test.

Signal president and CEO Sam Riccitelli said that with approval of MyPRS by the New York State Department of Health, the company is now available in all 50 US states to provide physicians and patients with a service to make better informed decisions when treating newly diagnosed or relapsed multiple myeloma.

"Most importantly, we will be entering a state with significant market opportunity. This approval makes MyPRS available to all of the more than 24,000 multiple myeloma patients diagnosed in the U.S. each year – further establishing our prognostic as a standard tool in the management of this difficult to treat disease," Riccitelli added.

MyPRS is a microarray-based gene expression profiling assay used to assist in treatment planning and disease management of patients with multiple myeloma and related disorders. By profiling the genomes of patients’ isolated plasma cells, MyPRS generates a personalized prognostic score and molecular subtype that may inform each patient’s specific therapeutic alternatives. Extensive clinical trials and international peer-reviewed studies reinforce the clinical validity and utility and prognostic performance of the test.